Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Rumbyrt

Allergy & Immunology Lakewood, CO Medical Doctor

NPI 1295735694 CMS profile 330548

1746 Cole Blvd, Suite 320, Lakewood, CO 80401

Open in the dashboard

General payments

$348,075

692 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,454,993 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeffrey Rumbyrt of Lakewood, CO is reported in the CMS Open Payments database as having received $348,075 across 692 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,454,993 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77,936 166
2024 General $65,729 114
2023 General $62,199 161
2022 General $61,639 112
2021 General $31,695 41
2020 General $17,841 36
2019 General $31,035 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Rumbyrt
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jeffrey Rumbyrt were reported at $77,936. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jeffrey Rumbyrt Allergy & Immunology median Middle half National median
2019 $31,035 $594 $163–$1,512 $163
2020 $17,841 $426 $106–$1,233 $114
2021 $31,695 $638 $157–$1,708 $132
2022 $61,639 $790 $205–$1,961 $149
2023 $62,199 $852 $220–$2,147 $160
2024 $65,729 $865 $203–$2,267 $164
2025 $77,936 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BioCryst US Sales Co., LLC $91,051 111 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $76,380 122 payments
  3. Pharming Healthcare, Inc. $67,057 102 payments
  4. Shire North American Group Inc $25,399 39 payments
  5. AstraZeneca Pharmaceuticals LP $18,201 63 payments
  6. AbbVie, Inc. $11,766 25 payments
  7. CSL Behring $11,748 42 payments
  8. Ionis Pharmaceuticals, Inc. $9,662 14 payments
  9. Grifols USA, LLC $8,021 21 payments
  10. Genentech, Inc. $5,820 8 payments
  11. Other $22,970 145 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $177,824 69 payments
  2. Consulting Fee $111,688 40 payments
  3. Travel and Lodging $33,901 181 payments
  4. Food and Beverage $12,827 392 payments
  5. Honoraria $11,750 4 payments
  6. Education $85 6 payments
Products named General payments · program years 2019–2025
  1. Orladeyo $83,231 109 payments
  2. RUCONEST $67,057 102 payments
  3. CINRYZE $58,815 82 payments
  4. TAKHZYRO $36,052 63 payments
  5. TEZSPIRE $16,598 36 payments
  6. RINVOQ $11,813 27 payments
  7. DAWNZERA $9,630 13 payments
  8. Xembify $7,983 18 payments
  9. Xolair $7,980 30 payments
  10. Andembry $7,567 11 payments
  11. Other $25,448 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

677

Median for Allergy/ Immunology: 449

Drug cost

$367,483

Median for Allergy/ Immunology: $169,700

Branded share of claims

61%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 38 $144,289
Dupixent Pen Dupilumab Brand 28 $115,313
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $19,854
Breo Ellipta Fluticasone/Vilanterol Brand 30 $13,610
Qvar Redihaler Beclomethasone Dipropionate Brand 33 $12,705
Symbicort Budesonide/Formoterol Fumarate Brand 26 $12,624
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 41 $8,775
Advair Diskus Fluticasone Propion/Salmeterol Brand 21 $7,385
Advair Hfa Fluticasone Propion/Salmeterol Brand 13 $5,966
Arnuity Ellipta Fluticasone Furoate Brand 20 $5,385

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$112,461

Of which drugs: $76,342

Medicare patients

203

Average age 72

Services billed

5,389

132 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 50%
Depression 22%
Osteoporosis 20%
Diabetes 16%
Chronic kidney disease 16%
COPD 16%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Orladeyo
  • BioCryst US Sales Co., LLC $19,661
$19,661 — —
RUCONEST
  • Pharming Healthcare, Inc. $16,894
$16,894 — —
TAKHZYRO
  • Takeda Pharmaceuticals U.S.A., Inc. $14,888
$14,888 — —
VTAMA
  • Dermavant Sciences, Inc. $4,507
$4,507 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $540
$540 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

692 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record